Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes

被引：0
|
作者：
Du, J. [1 ]
Wang, G. X. [2 ]
Wang, G. [3 ]
Liu, M. [4 ]
Thamattoor, U. K. [5 ]
Luan, Z. J. [6 ]
Alibegovic, A. C. [7 ]
Mu, Y. M. [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Jilin, Jilin, Peoples R China
[3] Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China
[5] Novo Nordisk India Private Ltd, Global Business Serv, Bangalore, Karnataka, India
[6] Novo Nordisk, Beijing, Peoples R China
[7] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [21] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Hanne Haahr
    Thomas R. Pieber
    Chantal Mathieu
    Theis Gondolf
    Masanari Shiramoto
    Lars Erichsen
    Tim Heise
    Clinical Pharmacokinetics, 2019, 58 : 639 - 649
  • [22] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes
    Twigg, Stephen
    Philis-Tsimikas, Athena
    Bode, Bruce
    Franek, Edward
    Rose, Ludger
    Buchholtz, Kristine
    Demissie, Marek
    Pieber, Thomas R.
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 64 - 64
  • [23] Improved glycaemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes
    Philis-Tsimikas, A.
    Bode, B. W.
    Franek, E.
    Rose, L.
    Buchholtz, K.
    Demissie, M.
    Pieber, T. R.
    DIABETOLOGIA, 2017, 60 : S315 - S315
  • [24] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    DIABETOLOGIA, 2011, 54 : S423 - S423
  • [25] Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
    Dutta, Deep
    Mohindra, Ritin
    Mahajan, Kunal
    Sharma, Meha
    DIABETES & METABOLISM JOURNAL, 2023, 47 (01) : 72 - 81
  • [26] Insulin degludec and insulin degludec/insulin aspart: A guide to their use in diabetes mellitus
    Keating G.M.
    Drugs & Therapy Perspectives, 2013, 29 (10) : 297 - 302
  • [27] Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    Raskin, P
    Riis, A
    Guthrie, RA
    Jovanovic, L
    Leiter, L
    DIABETES CARE, 2000, 23 (05) : 583 - 588
  • [28] Use of fast-acting insulin aspart in insulin pump therapy in clinical practice
    Evans, Mark
    Ceriello, Antonio
    Danne, Thomas
    De Block, Christophe
    DeVries, J. Hans
    Lind, Marcus
    Mathieu, Chantal
    Norgaard, Kirsten
    Renard, Eric
    Wilmot, Emma G.
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2039 - 2047
  • [29] Efficacy and safety of insulin degludec/insulin aspart vs biphasic insulin aspart 30: an international randomised trial in adults with type 2 diabetes fasting during Ramadan
    Hassanin, M.
    Echtay, A.
    Malek, R.
    Omar, M.
    Shaikh, S.
    Fita, E. G.
    Kaplan, K.
    Kamaruddin, N.
    DIABETOLOGIA, 2017, 60 : S75 - S75
  • [30] Fast-Acting Insulin aspart (faster aspart) - Clinical Data on Application in Type 1 and 2 Diabetes
    Jaeckel, E.
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (06): : 313 - 319
12345